Stopping long‐term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg‐negative chronic hepatitis B

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|38|S1|90-96

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.38, Iss.S1, 2018-02, pp. : 90-96

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Systematic review: cessation of long‐term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen‐negative chronic hepatitis B

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 3, 2015-08 ,pp. : 243-257

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects

By  

HEPATOLOGY, Vol. 62, Iss. 3, 2015-09 ,pp. : 684-693

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reduced risk of relapse after long‐term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 9, 2015-05 ,pp. : 867-876

John Wiley & Sons Inc

Access to resources Recommend Favorite

Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues

By  

Oncology, Vol. 90, Iss. 4, 2016-03 ,pp. : 199-208

Karger

Access to resources Recommend Favorite

P042: Hepatitis B surface proteins (SHBs, LHBs and MHBs) decline after stopping of nucleos(t)ide analogue therapy in HBeAg‐negative patients

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 40-40

John Wiley & Sons Inc

Access to resources Recommend Favorite